Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.
You may also be interested in...
Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.
Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.
Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.